Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Jackisch

Showing results (61-70 of 231) with videos related to

Pageof 24
Sort By:
Frontiers in Digital Health|August 29, 2024
Towards an early warning system for monitoring of cancer patients using hybrid interactive machine learningAndreas Trojan, Emanuele Laurenzi, Stephan Jüngling, et al.
Breast Care (Basel, Switzerland)|April 10, 2014
HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast CancerNadia Harbeck, Matthias W Beckmann, Achim Rody, et al.
Human Pathology|December 24, 2003
Secretory carcinoma of the breast: a distinct variant of invasive ductal carcinoma assessed by comparative genomic hybridization and immunohistochemistryRaihanatou Diallo, Karl-Ludwig Schaefer, Agnes Bankfalvi, et al.
Breast Care (Basel, Switzerland)|August 11, 2020
Assessment of Quality of Life in Postmenopausal Women with Early Breast Cancer Participating in the PACT Trial: The Impact of Additional Patient Information Material Packages and Patient ComplianceChristian Jackisch, Rolf Kreienberg, Maria Blettner, et al.
Clinical Breast Cancer|March 8, 2021
Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast CancerChristian Jackisch, Carlos H Barcenas, Rupert Bartsch, et al.
Breast Care (Basel, Switzerland)|January 15, 2014
Patient's Anastrozole Compliance to Therapy (PACT) Program: Baseline Data and Patient Characteristics from a Population-Based, Randomized Study Evaluating Compliance to Aromatase Inhibitor Therapy in Postmenopausal Women with Hormone-Sensitive Early Breast CancerNadia Harbeck, Maria Blettner, Peyman Hadji, et al.
Gynecologic Oncology|December 13, 2006
Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6)Uwe Wagner, Andreas du Bois, Jacobus Pfisterer, et al.
Journal of the National Cancer Institute|April 10, 2008
Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio studyGunter von Minckwitz, Sherko Kümmel, Petra Vogel, et al.
Journal of the National Cancer Institute|April 10, 2008
Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trialGunter von Minckwitz, Sherko Kümmel, Petra Vogel, et al.
Cancer Treatment Reviews|June 17, 2021
Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledgeChristian Jackisch, Patricia Cortazar, Charles E Geyer, et al.
Pageof 24

Showing results (61-70 of 231) with videos related to

Sort By:
Pageof 24
Frontiers in Digital Health|August 29, 2024
Towards an early warning system for monitoring of cancer patients using hybrid interactive machine learningAndreas Trojan, Emanuele Laurenzi, Stephan Jüngling, et al.
Breast Care (Basel, Switzerland)|April 10, 2014
HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast CancerNadia Harbeck, Matthias W Beckmann, Achim Rody, et al.
Human Pathology|December 24, 2003
Secretory carcinoma of the breast: a distinct variant of invasive ductal carcinoma assessed by comparative genomic hybridization and immunohistochemistryRaihanatou Diallo, Karl-Ludwig Schaefer, Agnes Bankfalvi, et al.
Breast Care (Basel, Switzerland)|August 11, 2020
Assessment of Quality of Life in Postmenopausal Women with Early Breast Cancer Participating in the PACT Trial: The Impact of Additional Patient Information Material Packages and Patient ComplianceChristian Jackisch, Rolf Kreienberg, Maria Blettner, et al.
Clinical Breast Cancer|March 8, 2021
Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast CancerChristian Jackisch, Carlos H Barcenas, Rupert Bartsch, et al.
Breast Care (Basel, Switzerland)|January 15, 2014
Patient's Anastrozole Compliance to Therapy (PACT) Program: Baseline Data and Patient Characteristics from a Population-Based, Randomized Study Evaluating Compliance to Aromatase Inhibitor Therapy in Postmenopausal Women with Hormone-Sensitive Early Breast CancerNadia Harbeck, Maria Blettner, Peyman Hadji, et al.
Gynecologic Oncology|December 13, 2006
Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6)Uwe Wagner, Andreas du Bois, Jacobus Pfisterer, et al.
Journal of the National Cancer Institute|April 10, 2008
Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio studyGunter von Minckwitz, Sherko Kümmel, Petra Vogel, et al.
Journal of the National Cancer Institute|April 10, 2008
Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trialGunter von Minckwitz, Sherko Kümmel, Petra Vogel, et al.
Cancer Treatment Reviews|June 17, 2021
Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledgeChristian Jackisch, Patricia Cortazar, Charles E Geyer, et al.
Pageof 24